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Summary
Congestive heart failure is a major problem in developed
and developing countries alike. Primary dysfunction of
the heart muscle accounts for a significant proportion of
patients with a non-ischaemic cause of heart failure.
Application of genetic techniques has facilitated identifi-
cation of some molecular causes of the inherited form of
these diseases, dramatically increasing our understand-
ing of the pathogenesis of these primary, previously
termed ‘idiopathic’, cardiomyopathies over the last few
decades. Knowledge of the different causes is beginning
to coalesce into aetiological principles underlying the
clinically distinguished cardiomyopathies. Hypertrophic
cardiomyopathy (HCM) now appears to be a disease
caused by a dysfunctional sarcomere, dilated cardiomy-
opathy (DCM), a disease of myocytic structural instabil-
ity, and arrhythmogenic right ventricular cardiomyopa-
thy, a disease of accelerated myocyte death. The aetiolo-
gy of both HCM and DCM probably also involves car-
diac energy imbalances, while additional factors modify
the clinical expression in all cardiomyopathies. Even
though our knowledge of the genetic aetiology of the car-
diomyopathies is still incomplete, it already has relevant
clinical significance. Elucidation of the full genetic con-
tribution to the development and progression of the car-
diomyopathies represents a new challenge in the study of
these diseases, and will undoubtedly lead to new thera-
peutic approaches in the not-too-distant future.
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Congestive heart failure is a major problem in developed and
developing countries alike. In Europe, 50 million of the pop-
ulation of 1 000 million suffer from heart failure,1 and in the
USA, 4.9 million patients are treated for heart failure each
year.2 Although it is difficult to obtain similar statistics for
South Africa, figures obtained from the Medical Research
Council report that deaths from all forms of cardiovascular
disease (CVD) account for about 22% of total mortality. 
Heart failure entails breakdown of the usually efficient
cardiac pumping mechanism and consequently failure to
meet the variable demands of the body’s tissues, and may be
either ischaemic or non-ischaemic in origin.3–6 Primary dys-
function of the heart muscle (cardiomyopathy) accounts for
a significant proportion of patients with a non-ischaemic
cause of heart failure.7 This dysfunction springs from active
remodelling of the myocardial structure of either one or both
ventricles, in an attempt to normalise an underlying fault in
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pump function. The remodelling usually involves hypertro-
phy of the individual myocytes, which may extend to the
whole ventricular myocardium and which may, for reasons
not completely clear, progress to cardiac dilation.8,9 Although
at first either of these types of myocardial change may be
beneficial, they become maladaptive with time. Both hyper-
trophy and dilation place greater energy demands on the
heart, and progressively escalate systolic and/or diastolic
dysfunction, placing the heart on a downward spiral towards
complete heart failure.
Originally, in the absence of aetiological clues, the car-
diomyopathies were grouped together as ‘idiopathic’ car-
diomyopathies and were sub-classified, by morphological
and haemodynamic characteristics, into five categories.
These were hypertrophic, dilated, arrhythmogenic right ven-
tricular and restrictive cardiomyopathy, as well as the broad
category of the unclassified cardiomyopathies.10 These
groupings are still convenient, although with increasing
understanding of the molecular basis of the inherited car-
diomyopathies, few of them remain idiopathic, and we also
now know that aetiological overlap occurs in these clinical-
ly differentiated disorders. New insights have been gained
most speedily and extensively for hypertrophic cardiomy-
opathy (HCM), followed by dilated cardiomyopathy
(DCM), while much still remains to be learnt about arrhyth-
mogenic right ventricular cardiomyopathy (ARVC) and
familial forms of restrictive cardiomyopathy (RCM).
Characteristic features of the different
cardiomyopathies
Clinical features
The distinguishing clinical, histological and symptomatic
features of the four categories of idiopathic cardiomy-
opathies are summarised in Table I. 
HCM features all aspects of a failing heart that has
remodelled according to the hypertrophic route. The disease
is generally characterised, morphologically, by hypertrophy
TABLE I. SUMMARY OF MORPHOLOGICAL, CLINICAL AND SYMPTOMATIC FEATURES
OF THE FOUR CARDIOMYOPATHIES
Cardiomyopathy HCM DCM ARVC RCM
Ventricles Left mostly Left mostly Right mostly Both
Hypertrophy of Dilation of ventricular Infiltration of RV free wall by Non-dilated,
ventricular wall chamber fibro-fatty tissue Non-hypertrophied,
Normal or thinned RV wall Non-compliant 
± RV dilation
Partial occlusion of Normal or thinned
ventricular ventricular walls
chamber
Variants Asymmetrical With or without Infiltration Amyloid
Concentric conduction defects Replacement of myocytes in Other
Apical RV free wall
Mid-cavity
DCM-like
Old age
Atria LA dilation LA or bi-atrial dilation RA dilation Bi-atrial dilation
Haemodynamic Reduced diastolic Reduced systolic & Some reduced systolic & Severely reduced 
function diastolic reduced diastolic diastolic
Electrophysiology Ventricular arrhythmias Ventricular arrhythmias Ventricular tachyarrhythmias AV block
± conduction defects ± conduction defects
Histology Pathological hypertrophy Apoptosis Infiltration by fibro-fatty tissue Amyloidosis
Fibrosis Inflammation Ischaemic damage
Myocytic disarray Hypertrophic &
atrophic fibres
Symptoms Dyspnoea, syncope, Fatigue, exercise Syncope, palpitations Systemic and pulmonary
angina, palpitations, intolerance, angina, venous congestion,
embolism, CHF CHF fibrillation
Prevalence 1:500 1:2 500 1:5 000 (Italy) Rare
Mode of inheritance Autosomal dominant Autosomal dominant, Autosomal dominant Possibly autosomal
autosomal recessive, dominant
X-linked
Familial rate >50% ~30% Unknown Unknown
Mode of death Mostly SUD SUD SUD SUD
CHF CHF
Phenocopies Noonan’s syndrome Skeletal myopathies Naxos disease Autosomal dominant
Friedreich’s ataxia Limb-girdle muscular familial amyloidosis
VLCAD deficiency dystrophies
Barth syndrome
LV = left ventricle, RV = right ventricle, LA = left atrium, RA = right atrium, SUD = sudden unexpected cardiac death, CHF = congestive heart failure, 
AV = atrio-ventricular, VLCAD = very-long-chain Acyl-CoA. 
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that most often affects the left ventricle and interventricular
septum and usually develops fully between puberty and the
third decade of life.11,12 HCM is extremely variable in terms
of its clinical presentation, the amount and location of hyper-
trophy, and the risk of sudden cardiac death.13 Depending on
the location of hypertrophy, HCM is subdivided into numer-
ous hypertrophic variants, some of which are now proposed
to be associated with specific genetic defects.14 Electro-
cardiographically, the most important feature in terms of out-
come is ventricular tachyarrhythmias that can be life-threat-
ening, while left ventricular hypertrophy with or without 
ST-T waves and Q-wave changes is important in the diagno-
sis of the condition.15
DCM, on the other hand, is the classic example of a heart
remodelled in keeping with the dilation route. In this disor-
der, morphologically, all cardiac chambers are usually
enlarged, and the dilation can occur in the presence of nor-
mal or thinned cardiac walls, with concomitant systolic and
diastolic dysfunction. Electrophysiologically, these dilated
hearts are also prone to ventricular arrhythmias, which can,
as with HCM, lead to sudden cardiac death.10
In ARVC, it is most often the right ventricle that is affect-
ed by infiltration of the ventricular wall, or replacement of
the myocytes in this wall by a fibro-fatty tissue.16,17 These
hearts are prone to premature beats and ventricular tachycar-
dia, which may be provoked by exercise-induced cate-
cholamine release and thus may cause sudden cardiac death
during physical activity.16
In RCM, both ventricles are non-compliant, causing end-
diastolic pressures to increase and both atria to dilate. In pri-
mary, idiopathic RCM the ventricles are neither dilated nor
hypertrophied; however, secondary RCM may be due to
infiltration of the heart muscle by amyloid or sarcoid fibrils,
or can be a feature of late stages of DCM, HCM, hyperten-
sive, valvular and ischaemic heart disease.18 These infiltra-
tive forms of RCM may be accompanied by increased wall
thickness. Atrial fibrillation due to atrial dilation is a com-
mon feature of RCM.18
Diagnosis
Clinical diagnosis of the cardiomyopathies relies extensive-
ly on techniques that allow measurement of functional para-
meters and visualisation of macroscopic and microscopic
morphological features of the heart. HCM is therefore diag-
nosed when ventricular wall thickness is equal to or exceeds
13 mm on echocardiography in the absence of another cause
such as hypertension or aortic stenosis.19 DCM is diagnosed
when there is impaired systolic function (ejection fraction
< 45% or fractional shortening < 25%) and left ventricular
cavity size > 112% of predicted normal values.20 In most
cases of ARVC, the disease can only be diagnosed by elabo-
rate investigation, involving family history, electro- and
echocardiography, right ventricular angiography and con-
trast ventriculography, and histological examination of the
right ventricular free wall. Because of this difficulty in diag-
nosis, the present diagnosis for ARVD, in the absence of a
histological finding of fibro-fatty infiltration of the right ven-
tricular myocardium, requires that a patient demonstrate
either two major, one major plus two minor, or at least four
minor diagnostic criteria.16,21 Primary RCM is diagnosed on
the basis of restrictive filling and reduced diastolic volume
of either or both ventricles with normal systolic function and
wall thickness, in the absence of another cause. The features
may be found on echocardiography, but cardiac catherisation
and endomyocardial biopsy are required for diagnosis.10,18,22
Histology
As an adjunct to clinical diagnosis, the four types of prima-
ry cardiomyopathy can also be distinguished on histological
examination of endomyocardial biopsy. However, diagnosis
by endomyocardial biopsy may not be definitive in all cases.
Specifically, absence of abnormal histological findings can
be due to the segmental nature of myocardial involvement in
the cardiomyopathies.
HCM is characterised by pathological hypertrophy of the
individual myocytes, but the characteristic feature of HCM
is myocytic and myofibrillar disarray. This disturbance of the
normally extremely ordered cardiac syncytium, present to a
lesser extent in other cardiac disorders as well as in normal
hearts, has been found to affect up to 30% of total tissue
studied in HCM hearts.23 In DCM, the histology is usually
non-specific, showing mild interstitial fibrosis, some degree
of myocardial cell degeneration and apoptosis, while
myocyte hypertrophy is uniform and disarray absent.9,24 The
frequency of ‘ghost’ myocytes, lacking myofibrillar ele-
ments, has been correlated with the degree of dilation and
severity of symptoms in DCM.25 For ARVC diagnostic pur-
poses, infiltration of the myocardium by fibrous tissue
should be seen in more than 3%, and by fatty tissue in more
than 40%, of biopsy sections; there are also usually signs of
inflammation and areas of apoptosis.16,26 In RCM, pericellu-
lar fibrosis is evident, while there may be some evidence of
myocyte hypertrophy, attenuation and degredation.18
Additionally, histology is vital in the diagnostic work-up of
patients with RCM to exclude amyloidosis, haemochro-
matosis and sarcoidosis. 
Sudden cardiac death
Although there is symptomatic overlap between these four
categorised disorders (Table I), they can and should be dis-
tinguished by the cardiologist for appropriate management
of patients. However, these cardiomyopathies are highly
variable in their clinical presentation. Many patients remain
asymptomatic for years and consequently only seek medical
attention when the condition is quite advanced.
Frighteningly, these cardiomyopathies often result in sudden
cardiac death, frequently among the young, asymptomatic
and apparently healthy and health-conscious, with the con-
comitant shock, grief and regret amongst those that remain.
In fact, worldwide, HCM is considered to be the most com-
mon cause of sudden cardiac death among young, healthy
individuals and athletes,27 except in the Far East and in Italy,
where it is reported that 20–25% of these deaths are caused
by either idiopathic ventricular tachycardia or ARVC.28,29
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Frequently, it is only enquiries initiated by these sudden
deaths that trigger, in both the clinician and the family, an
awareness of the possible familial nature of the disease and,
consequently, additional at-risk family members may be
identified at an earlier stage.
Genetics of the cardiomyopathies
Lessons from genetics
Our understanding of the molecular aetiologies of the car-
diomyopathies appears to be commensurate with the avail-
ability of large families in which the disease segregated
through multiple generations, which facilitated molecular
genetic investigations of the underlying cause, at least in the
inherited forms of these disorders. These studies have also
lead to a greater awareness of the subtle clinical manifesta-
tions and occurrence of these diseases in the general popula-
tion. Therefore, although HCM used to be considered quite
rare,24 it is now recognised to be one of the most common
inherited cardiac disorders, with a prevalence rate (1:500)
similar to that estimated worldwide for the common inherit-
ed disease, familial hypercholesterolaemia.30 Also, knowl-
edge of the genetic defects that underlie some of the inherit-
ed cardiomyopathies has allowed DNA-based screening for
mutation-carriers, and a clearer picture of disease penetrance
(the risk of development of clinical disease in these individ-
uals) as well as the mode of inheritance has emerged (Table
I). The identification of numerous clinically unaffected
mutation-carriers has also lead to the realisation that many
more cases of cardiomyopathy are familial than was origi-
nally thought, that the clinical manifestation of the disease is
modified by additional factors, and that mortality figures
attributable to cardiomyopathy are probably lower than at
first estimated.
In addition, besides the classic cardiomyopathies dis-
cussed above, numerous syndromic diseases exist in which a
form of cardiomyopathy is merely one of many clinical fea-
tures (Table I). These phenocopies of the cardiomyopathies
had generally been dismissed as unlikely to provide clues in
the search for the molecular cause of the pure cardiomy-
opathies. However, recently, elucidation of the molecular
lesions underlying some syndromes of which cardiomyopa-
thy is a feature has added tremendously to our understanding
of the underlying pathophysiological principles, which may
also be applicable to the non-inherited forms of the different
cardiomyopathies.
HCM – a ‘sarcomeropathy’…
The large families with multiple individuals unequivocally
affected with uncomplicated HCM, as described in the early
to mid 1900s,31,32 made this cardiomyopathy most amenable
to molecular genetic analysis. So, over the last 10 years, 
and at an ever-increasing rate, more and more evidence
indicated that HCM is a ‘sarcomeropathy’.33 Currently, 
it is known that many cases of sporadic and familial HCM
are caused by more than 150 distinct mutations in at least
nine different genes encoding protein components of the
contractile unit of cardiac muscle, the sarcomere (Table II,
Fig. 1) (FHC database). This knowledge has been useful in
explaining many clinical features of the disease and has 
also become a valuable adjunct to clinical diagnosis,
management and counselling of HCM-affected patients.
Probably the most useful corollary of aetiological under-
standing was the discovery of correlations between specific
genetic defects and the clinical outcome. Significantly, these
defects appeared to correlate better with disease prognosis
than did any clinical parameter tested to date, and this was
applicable to carriers of any age. Some mutations were
associated with normal life expectancy, while others were
associated with a high risk of sudden cardiac death.34,35,39
It also became clear that, although extreme hypertrophy is
still a predictor of poor prognosis,36 hypertrophy in general,
and risk of sudden cardiac death are unrelated features 
(Fig. 2).35,39 In fact, it was found that defects in some of 
these sarcomeric protein-encoding genes, e.g., troponin T
(Fig. 1), often cause minimal hypertrophy (Fig. 2a), yet 
are associated with early sudden cardiac death (Fig. 2b).35,37–39
In a South African study, it was found that this was especial-
ly true in young male carriers of the troponin T R92W
mutation.35,39 Significantly, this mutation shows a founder
effect, i.e. it is enriched in the South African population due
to sub-population history.40
In addition, there have been indications that some of the
morphological variants of hypertrophy (Table I) are associ-
ated with specific genes or mutations (Table II). For
instance, the troponin T R92W mutation has been associat-
ed, in Japanese patients, with the DCM-like variant with
early cardiac decompensation and progression from hyper-
trophy to dilation.41 Other, sometimes weaker, associations
have been demonstrated between particular defects and the
apical variant (troponin I, Fig. 1),42 or the mid-cavity variant
(myosin light chains, Fig. 1),43 or the variant in which hyper-
trophy does not stop after the third decade, but progresses
throughout life, akin to the hypertrophy of old age (myosin
binding protein-C, Fig. 1).44,45
Studies of the functional effects of these mutations indi-
cated that the encoded faulty proteins become ‘poison pep-
tides’ that disrupt the function and the structure of the sar-
comere, and may directly give rise to extensive myofibrillar
and myocytic disarray, characteristic of HCM.46,47 These
functional studies also revealed that most HCM-causing
defects result in abnormal calcium (Ca2+) sensitivity of con-
tractility,48 supporting the earlier observation of altered Ca2+
handling by HCM hearts.49,50 In addition, it was found that
some defects give rise to myofibres that are hypercontractile,
fitting the early ‘pre-gene era’ observation of apparent
hypercontractility in HCM.51 Yet, other defects give rise to
myofibres that are hypocontractile,48 which begs the ques-
tion: ‘how can both hypo- and hypercontractile fibres pro-
duce essentially the same clinical entity?’. Moreover, any
aetiological connection between phenocopies of HCM,
which do not feature sarcomeric disruption, and classic
HCM remained elusive until last year, when mutations in the
5ı-activated AMP protein kinase (AMPK) gene were found
in individuals featuring HCM and Wolf-Parkinson-White
syndrome (HCM+WPW).52
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TABLE II. MOLECULAR CAUSES OF THE CARDIOMYOPATHIES.
Cardio- Gene product Cellular location/
myopathy Chromosome (gene symbol) function Clinical phenotype Reference
HCM 14q11-12 Cardiac β-myosin Sarcomere (thick filament) Variable hypertrophy, variable
heavy chain (MYH7) SUD 39, 93, 94
1q32 Cardiac troponin T Sarcomere (thin filament) Minimal hypertrophy, high risk 35, 41
(TNNT2) of SUD, fast progression to 
DCM-like variant
11p11.2 Cardiac myosin Sarcomere (thick filament) Progressive hypertrophy (old age- 45, 95
binding protein-C variant), more HF than SUD
(MYBPC3)
15q22 α-tropomyosin Sarcomere (thin filament) Variable, but usually good 96, 97, 98
(TPM1) prognosis; some progress to
DCM-like variant
19q13.4 Cardiac troponin I Sarcomere (thin filament) Apical variant, old-age variant,
(TNNI3) some progress to DCM-like variant 42, 45, 99
12q23-24 Ventricular myosin Sarcomere (thick filament) Some demonstrate mid-cavity variant 43, 100
regulatory light chain
(MYL2)
3p21 Myosin essential Sarcomere (thick filament) Some demonstrate mid-cavity variant 143, 101
light chain (MYL3)
15q14 Cardiac actin (ACTC) Sarcomere (thin filament) Rare 102
2q31 Titin (TTN) Sarcomere Rare 103
14q11-12 Cardiac α-myosin Sarcomere (thick filament) Rare; old-age variant 45
heavy chain (MYH6) 
7q35 Cardiac 5ı-AMP Enzyme, senses falling + Wolff-Parkinson-White syndrome, 52, 56
activated protein kinase ATP levels glycogen storage disease
(PRKAG2)
DCM Xp21 Dystrophin (DMD) Intracellular cytoskeleton ± Duchene’s or Becker’s muscular 62, 63
dystrophies, rapid progression to HF
2q35 Desmin (DES) Intracellular cytoskeleton + Desmin myopathy 68, 104
5q33-34 δ-sarcoglycan (SGCD) Cell membrane, + Limb girdle muscular dystrophy 65, 105
extracellular matrix 2F, early onset dilation
6p24 Desmoplakin (DSP) Desmosomal junction + Keratoderma and woolly hair 106
1q21.3 Lamin A/C (LMNA) Inner nuclear membrane Often with conduction defects, 67, 107
± Emery-Dreifuss muscular 
dystrophy, limb girdle muscular 
dystrophy 2B
Xq28 Emerin (EMD) Inner nuclear membrane + Emery-Dreifuss muscular 66
dystrophy
1q32 Cardiac troponin T Sarcomere (thin filament) Early dilation 108, 109
(TNNT2)
14q11-12 Cardiac β-myosin Sarcomere (thick filament) Early dilation 108
heavy chain (MYH7)
2q31 Cardiac titin (TTN) Sarcomere (M-line-Z-disk) Rare 72
15q14 Cardiac actin (ACTC) Sarcomere (thin filament) + Nemaline myopathy 71
15q22 α-tropomyosin (TPM1) Sarcomere (thin filament) + Nemaline myopathy 110
Xq28 Tafazzin (G4.5) Enzyme, produces + Barth syndrome, infantile onset 77
glycophospholipid of inner
mitochondrial membrane
9q13-22 Unknown Unknown Incomplete penetrance 111
10q21-23 Unknown Unknown Mitral valve prolapse 112
2q14-22 Unknown Unknown Frequent ventricular tachycardia 113
3p22-25 Unknown Unknown Sick sinus syndrome and stroke 114 
6q23 Unknown Unknown + Adult onset limb-girdle muscular 115
dystrophy and conduction defects
6q23-24 Unknown Unknown + Juvenile sensorineural hearing loss 116
ARVC 17q21 Plakoglobin Desmosomal junction + Naxos disease 83
1q42 Cardiac ryanodine Regulates Ca2+ release from Particularly high risk of sudden 80
receptor sarcoplasmic reticulum death upon exercise (ARVC2) 80
2q32 Unknown Unknown Unknown 117
3p23 Unknown Unknown Unknown 118
14q12-22 Unknown Unknown Unknown 119
14q23-24 Unknown Unknown Unknown 120
10p12-14 Unknown Unknown Unknown 121
HF = heart failure; SUD = sudden cardiac death. 
… and an energy-deficiency disorder?
The AMPK enzyme acts as the fuel gauge of the myocyte,
sensing when adenosine triphosphate (ATP) levels in the
extremely energy-sensitive myocyte run too low, and acti-
vating molecular pathways that lead to increased energy pro-
duction.53,54 Although mutations in different subunits of
AMPK are also associated with features of glycogen storage
disease, so that HCM+WPW may represent yet another phe-
nocopy of primary HCM, they are invariably associated with
muscle hypertrophy.55,56 This has lead to the proposal that the
common underlying aetiological principle of cardiac hyper-
trophy, whether in HCM or in HCM-phenocopies, relates to
an inequality in energy supply and demand.52 In HCM, both
hypercontractile and hypocontractile fibres waste energy,
directly by overactivity, or by creating drag on unaffected
fibres, respectively. Similarly, in the HCM-phenocopy dis-
eases such as mitochondrial mutation-related disorders,57
Friedreich’s ataxia58 or very-long-chain acyl-CoA dehydro-
genase (VLCAD) deficiency,59 the underlying mechanism
relates to ineffective energy production in the mitochondria,
and in HCM+WPW the sensing mechanism that should nor-
mally activate energy-producing pathways is defective.52,56
Moreover, it can be speculated that the aetiological principle
underlying cardiac hypertrophy in hypertension may well be
the same, as greater resistance in the vessels will increase
energy demands in the heart in order to maintain pumping
effectiveness. Whatever the primary cause of the energy
imbalance, chronic decreased ATP levels will impede Ca2+
re-uptake from the cytoplasm into the sarcoplasmic reticu-
lum by the Ca2+ ATPase, SERCA2a, and so lead to Ca2+-
related activation of hypertrophic and arrhythmic path-
ways.60,61
DCM – a ‘cytoskeletopathy’…
Elucidation of the molecular underpinnings of DCM (Table
II) has been more intractable than for HCM, perhaps reflect-
ing the greater complexity in terms of familial and environ-
mental causes of the former disorder. Unlike HCM, which is
a genetic disorder in the majority of cases, only a minority
(about 30%) of patients with DCM have evidence of famil-
ial clustering. Even less commonly, DCM is a feature of syn-
dromic disorders, often with accompanying skeletal and
limb-girdle myopathies. Interestingly, it was this co-exis-
tence of DCM and skeletal myopathy in Duchenne’s and
Becker’s muscular dystrophies that lead to the discovery of
dystrophin (Fig. 1) defects as a cause of pure X-linked
DCM, without overt skeletal involvement,62,63 and to the
consequential speculation that, much as HCM is a ‘sarcom-
eropathy’, familial DCM is a ‘cytoskeletopathy’.64
Additional studies in other skeletal myopathy phenocopies
of DCM, which implicated more proteins that make up the
internal structure of the cell, the cytoskeleton (Fig. 1),
strengthened this proposal. Furthermore, it was not only the
internal cytoskeleton that was responsible, because proteins
that form part of the extracellular matrix function in cell:cell
contact at myocyte junctions (β- and δ-sarcoglycan, desmo-
plakin; Fig. 1),65 proteins that stabilise the membrane around
the cellular nucleus (lamin A/C, emerin; Fig. 1)66,67 and
proteins that connect these elements (desmin; Fig. 1)68 were
also found to be defective in patients with dilated hearts
(Table II). Moreover, the discovery that a number of
cytoskeletal proteins form substrates for proteases expressed
by viruses known to cause cardiac dilation69,70 may imply that
the aetiological principle involved in DCM may be instabil-
ity at any structural point throughout the integrated sub-
structure of the cardiac syncytium. 
Very recently, several of the sarcomeric protein-encoding
genes originally implicated in HCM (Table II, Fig. 1), have
also been found to be defective in some DCM cases, blurring
the lines of aetiological distinction between these two disor-
ders.71,72 It may be that these particular mutations cause DCM
rather than HCM because they involve different functional
domains of these proteins, or simply because the sarcomere
itself, although primarily a functional unit in the myocyte,
inherently also forms part of the integrated internal structure
of these cells. 
…with energy metabolism involvement?
However, to add to the complexity, it seems that DCM is
also not purely a disease of cell architecture, but that energy
metabolism could play a major role here as well, as is now
postulated for HCM. It has long been known that mitochon-
drial DNA defects have been associated with DCM,73–76
however, it has been difficult to prove whether these mito-
chondrial defects are the cause or consequence of the cardiac
phenotype. Recently, though, Barth syndrome, a DCM
phenocopy disorder, was found to be caused by defects in
the gene encoding the enzyme tafazzin, which results in a
failure to produce a specific glycerophospholipid.77,78
As this lipid forms part of the inner mitochondrial mem-
brane, mitochondrial dysfunction and therefore reduced
energy supply is implicated as the cause of DCM. This find-
ing is interesting in the light of data from previous morpho-
metric studies of mitochondria in biopsies from DCM and
HCM hearts, which suggested that the mitochondria of
DCM hearts showed decreased activity, while those from
HCM hearts showed increased activity.79
Many familial DCM-causing genes are currently only
localised to particular chromosomal regions and not yet
identified. However, the discovery of the responsible 
genes may be facilitated by combining our new under-
standing of the structural/architectural and energetic
aetiological principles underlying DCM with the deluge of
genetic data emanating from the human genome project.
Consequently, it can be anticipated that pinpointing 
DCM-causing genes may well enter the fast track, in parallel
with developments in HCM gene identification through the
last decade.
ARVC – myocyte death?
Although ARVC was particularly slow to reveal its aetiolog-
ical secrets, with originally some speculation only but no
concrete proof concerning the involvement of viruses, its
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familial nature became clear in time and lead to some eluci-
dation of its aetiology (Table II). Defects in the ryanodine
receptor were implicated as the cause of pure ARVC,80–82
while studies of the molecular cause of Naxos disease, a
complex phenocopy of ARVC, pointed to structural proteins
whose role is to maintain stability of the cardiac desmo-
somes.83 Initially the involvement of the former protein may
seem to imply a different molecular mechanism than that
proposed for Naxos disease. However, the ryanodine recep-
tor regulates the release of Ca2+ from the sarcoplasmic retic-
ulum, and failure to do so may lead to cell death by Ca2+
overload. Similarly, destabilisation of the desmosomes may
also cause cell death, unifying these apparently divergent
aetiological principles for ARVC, and perhaps providing the
explanation for the extensive myocyte loss seen in ARVC.
To date, there is no clue as to why these dead cells are
replaced by fibro-fatty tissue, or why the right ventricle is
most severely affected. From molecular genetic studies in
ARVC families, it is clear that the genes implicated so far are
not the only ones responsible for this cardiac phenotype, and
it is possible that with identification of more ARVC-causing
genes, these two features of the disease may become more
readily understood.
Modifier effects in cardiomyopathies
As with all inherited diseases, the inherited cardio-
myopathies also feature extensive variability in pheno-
typic expression, even between related carriers of the 
same disease-causing mutations. Moreover, in HCM, the
same disease-causing mutations have also been associated
with diverse clinical outcomes in families from different
ethnic ancestry.84 This indicates that additional factors,
genetic or environmental, which are neither necessary nor
sufficient to cause clinical disease, modulate the expression
of the primary ‘disease-trigger’. The identity of these
modifiers remains largely unknown, although a number 
of factors, such as components of the renin-angiotensin
system,85–88 mitochondrial variations,89,90 peptide hormones87
and trophic factors91 have been suggested. Furthermore,
identification of these modifying factors is complicated by
the genetic and allelic heterogeneity of the cardio-
myopathies. Large-scale systematic studies, either in
transgenic animals or in patients sharing the same muta-
tion and genetic background (founder cohorts) are likely 
to provide the most insight into the identities of these 
modulators.
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Fig. 1. Cellular localisation and interactions of proteins involved in HCM and DCM. Schematic representation of a
section through part of a cardiac myocyte, illustrating the position and interactions of many of the various proteins
that have been implicated in HCM and/or DCM.
Impact of genetic knowledge on
patient management and treatment
Even though our knowledge on the genetic aetiology of the
inherited cardiomyopathies is still incomplete, it is clinically
relevant.15,92 Although not all cases of cardiomyopathy will
be due to inherited genetic defects, the frequency of familial
forms has highlighted the need for a complete and detailed
family history, as well as for clinical follow-up and coun-
selling of all first-degree relatives of newly diagnosed car-
diomyopathy patients. It has become clear that a much lower
diagnostic threshold is appropriate when interpreting diag-
nostic tests in first-degree relatives of affected patients, par-
ticularly in family screening for HCM.15 Where DNA-based
genetic diagnosis is practicable, it allows early detection of
individuals at risk; this may be particularly relevant in cases
where a mutation is associated with a subtle clinical pheno-
type but a significant increase in risk of SUD. However, it
should be emphasised that, because of the aetiological het-
erogeneity underlying the cardiomyopathies, genetic diagno-
sis is currently most feasible for the inherited cardiomy-
opathies and in a family setting. Diagnosis is still mostly per-
formed at a research level by research institution laboratories
acting as referral centres.* 
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Fig. 2. Hypertrophy and risk of sudden cardiac death
in individuals carrying HCM-causing mutations.
(a) Comparison of the extent of hypertrophy in family
members with single distinct HCM-causing mutations in
different sarcomeric protein encoding genes.
(b) Kaplan-Meyer product limit curves for survival
amongst the mutation carriers in these families.
For some mutations (R403W, R92W), the majority
of individuals do not meet the clinical diagnostic
criterion of a maximum left ventricular wall thickness
(MLVWT) ≥13 mm [indicated by arrow in (a)], yet they
can still be at risk of early sudden cardiac death (R92W).
Troponin T – R92W; cardiac β-myosin heavy chain –
R249Q, R403W, A797T; cardiac myosin binding protein-
C – R654H, V896M.
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Conclusion
Our understanding of the pathogenesis of cardiomyopathies
has increased dramatically over the last few decades, due to
the identification of some molecular causes of the inherited
form of these diseases. Elucidation of the full spectrum of
genetic contribution to the development and progression of
the cardiomyopathies represents a new challenge in the
study of these diseases and will undoubtedly lead to new
therapeutic approaches in the not-too-distant future.
*Information about relevant laboratories in South Africa is avail-
able from the corresponding author, Johanna Moolman-Smook.
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